1h Free Analyst Time
The Asthma Therapeutics Market size was estimated at USD 24.70 billion in 2023, USD 27.26 billion in 2024, and is expected to grow at a CAGR of 10.63% to reach USD 50.10 billion by 2030 . Speak directly to the analyst to clarify any post sales queries you may have.
The asthma therapeutics market encompasses all activities related to the research, development, production, and distribution of medications and treatments designed to manage and alleviate the symptoms of asthma, a chronic respiratory disorder. This market serves a diverse population of patients across age groups who require either maintenance therapy or acute care for asthmatic episodes. The market scope includes various therapeutic products such as anti-inflammatory drugs, bronchodilators, combination therapies, biologics, and delivery devices such as inhalers and nebulizers. The primary applications within the asthma therapeutics market include long-term control medicines, which aim to maintain a stable condition, and quick-relief treatments for sudden symptoms. End-users of these products typically entail individuals diagnosed with asthma, healthcare professionals like pulmonologists, and healthcare settings, including hospitals, clinics, and homecare environments. The scope extends to support services like patient education and training on the proper use of asthma management devices. The need for asthma therapeutics is increasing due to growing incidences of asthma and other respiratory diseases, recent improvements in allergy detection and diagnostic technologies, and extensive demand for monoclonal antibodies. However, the asthma therapeutics market faces certain challenges, including limitations and side effects of asthma therapeutic devices, high costs associated with advanced treatments, and limited therapeutic reach in remote and rural areas. On the other hand, several opportunities are emerging within the asthma therapeutics market, including the development of combination therapeutics for the treatment and extensive research and development (R&D) efforts for asthma treatment. There is also an increasing trend towards digital health solutions, such as smart inhalers that can track usage and remind patients about doses, opening opportunities for tech companies and pharmaceutical partnerships.
Regional Insights
In the United States, the asthma therapeutics market is driven by a high prevalence of asthma alongside strong healthcare infrastructure. Patent expirations, novel biologics, and personalized medicine drive research and innovation in the region. Various organizations in the region continue to find a cure for and control asthma, food allergies, nasal allergies, and other allergic diseases. South America shows a growing need for asthma therapeutics, largely due to increasing awareness of respiratory diseases and improving healthcare facilities. Europe represents a substantial market for asthma therapeutics, supported by high awareness levels, established healthcare systems, and favorable reimbursement policies. The presence of several key market players and a strong emphasis on research and development activities are notable factors. Western European countries, including Germany, France, Switzerland, the United Kingdom, France, and Italy, hold a major market share, while Eastern European countries exhibit potential for growth due to improving healthcare infrastructure and rising asthma prevalence. The market in the Middle East is advancing with the development of healthcare infrastructure and increasing private sector investment. In contrast, Africa faces challenges such as limited healthcare services, low awareness, and inadequate access to treatment, which hinder market growth. However, certain countries, including South Africa, are making strides in asthma care, which can positively influence regional market development. In APAC, China's asthma therapeutic market is developing rapidly due to the growing middle class and enhanced healthcare reforms. In Japan, patients have access to several state-of-the-art treatments, reflecting the country's advanced healthcare system and high patient awareness. Japan's pharmaceutical sector is highly innovative, with a robust pipeline of new drugs and consistent investment in R&D. India's asthma treatment market is characterized by a need for affordable medications and increased education on asthma management. The high population, coupled with pollution issues, contributes to a growing prevalence of asthma. Government programs and non-profit initiatives aim to enhance asthma care accessibility and affordability throughout the subcontinent.Product: Rising demand for metered dose inhalers for the treatment of asthma
Inhalers are commonly prescribed devices used by asthma patients to give medication directly to the lungs, providing immediate relief and long-term control. Dry powder inhalers (DPI) are breath-actuated devices with medicines to the lungs as a dry powder. Unlike other inhalers, DPIs do not require propellants to dispense the medication. Instead, patients must inhale quickly and deeply to ensure the powder is drawn into the lungs. DPIs are commonly prescribed for the maintenance treatment of asthma as they provide a pre-measured dose and are often considered more environmentally friendly compared to traditional metered-dose inhalers. Metered dose inhalers (MDI) are the most widely used inhalers and rely on a propellant to deliver a precise dose of medication to the lungs. Patients need to coordinate their breath with the actuation of the device. Soft mist inhaler (SMI) is a newer category of inhaler that produces a fine mist designed to enhance medication delivery to the lungs. They use mechanical force to generate a slow-moving aerosol cloud that can be easily inhaled. SMIs are less dependent on patient inhalation techniques compared to DPIs and MDIs. This feature makes them potentially more suitable for patients with difficulty with the inhalation required for DPIs or the hand-breath coordination needed for MDIs. Nebulizers are asthma therapeutic devices that convert liquid medication into a fine mist for inhalation, typically over a longer period than inhalers. They are particularly beneficial for patients who are unable to use inhalers effectively, such as young children and the elderly. Nebulizers require an external power source and are less portable than inhalers. They can be used for maintenance and rescue treatment and are often used during severe asthma exacerbations. Nebulizers are asthma therapeutic devices that convert liquid medication into a fine mist for inhalation, typically over a longer period than inhalers. They are particularly beneficial for patients who are unable to use inhalers effectively, such as young children and the elderly. Nebulizers require an external power source and are less portable than inhalers. They can be used for maintenance and rescue treatment and are often used during severe asthma exacerbations.Drug Class: Growing usage of anti-Inflammatory drugs in asthma therapeutics
Anti-inflammatory drugs are the cornerstone of asthma therapeutics, primarily aimed at reducing inflammation and swelling in the airways, an underlying cause of asthma symptoms. They are typically the first line of defense in asthma control. Glucocorticoids, such as fluticasone and budesonide, are widely prescribed for their capacity to reduce inflammation in the airways. These medications are available in various forms, including inhalers and pills. The inhaled form is preferred due to lower systemic side effects. Bronchodilators relax the muscles surrounding the airways, alleviating signs such as wheezing, shortness of breath, and coughing. They are divided into short-acting beta-agonists (SABAs) and long-acting beta-agonists (LABAs). SABAs, such as albuterol, are used for immediate relief during an asthma attack. They are a must-have for all asthma patients for rescue purposes. LABAs, such as salmeterol, are used for long-term control and prevention of symptoms, particularly in combination with inhaled steroids, but are not for acute episodes. Combination therapies that include anti-inflammatory agents and bronchodilators are increasingly preferred for moderate to severe asthma cases. They provide the benefit of multiple mechanisms of action in one inhaler. Common combinations such as fluticasone/salmeterol and budesonide/formoterol offer convenience and improved compliance with fewer side effects than increasing the dose of steroids alone. When comparing these drug classes, anti-inflammatories are pivotal for long-term management. Bronchodilators act fast and are crucial for acute relief but don't address inflammation. Combination therapies provide a holistic approach but can be overprescribed for milder cases.Route of administration: Expanding adoption of inhaled asthma medication for fast relief
Inhaled therapeutics are the cornerstone of asthma treatment. By giving medication directly to the lungs, inhaled therapeutics aim to reduce side effects and improve drug efficacy. The need for inhaled asthma medication is generally higher in patients who require fast relief from acute asthmatic episodes or for those with chronic asthma who need regular administration of medicine to keep their symptoms under control. Oral medications are an alternative to inhaled therapies and are usually prescribed for mild asthma or in cases where inhalers are not the suitable choice. The standard oral treatments include leukotriene modifiers, theophylline, and oral corticosteroids. These are generally preferred when patients have difficulty using inhalers due to coordination issues or other health problems. Oral medications tend to have a systemic effect, which may lead to an increased possibility of side effects compared to inhaled therapies.Market Dynamics
The market dynamics represent an ever-changing landscape of the Asthma Therapeutics Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.Market Disruption Analysis
The market disruption analysis delves into the core elements associated with market-influencing changes, including breakthrough technological advancements that introduce novel features, integration capabilities, regulatory shifts that could drive or restrain market growth, and the emergence of innovative market players challenging traditional paradigms. This analysis facilitates a competitive advantage by preparing players in the Asthma Therapeutics Market to pre-emptively adapt to these market-influencing changes, enhances risk management by early identification of threats, informs calculated investment decisions, and drives innovation toward areas with the highest demand in the Asthma Therapeutics Market.Porter’s Five Forces Analysis
The porter's five forces analysis offers a simple and powerful tool for understanding, identifying, and analyzing the position, situation, and power of the businesses in the Asthma Therapeutics Market. This model is helpful for companies to understand the strength of their current competitive position and the position they are considering repositioning into. With a clear understanding of where power lies, businesses can take advantage of a situation of strength, improve weaknesses, and avoid taking wrong steps. The tool identifies whether new products, services, or companies have the potential to be profitable. In addition, it can be very informative when used to understand the balance of power in exceptional use cases.Value Chain & Critical Path Analysis
The value chain of the Asthma Therapeutics Market encompasses all intermediate value addition activities, including raw materials used, product inception, and final delivery, aiding in identifying competitive advantages and improvement areas. Critical path analysis of the <> market identifies task sequences crucial for timely project completion, aiding resource allocation and bottleneck identification. Value chain and critical path analysis methods optimize efficiency, improve quality, enhance competitiveness, and increase profitability. Value chain analysis targets production inefficiencies, and critical path analysis ensures project timeliness. These analyses facilitate businesses in making informed decisions, responding to market demands swiftly, and achieving sustainable growth by optimizing operations and maximizing resource utilization.Pricing Analysis
The pricing analysis comprehensively evaluates how a product or service is priced within the Asthma Therapeutics Market. This evaluation encompasses various factors that impact the price of a product, including production costs, competition, demand, customer value perception, and changing margins. An essential aspect of this analysis is understanding price elasticity, which measures how sensitive the market for a product is to its price change. It provides insight into competitive pricing strategies, enabling businesses to position their products advantageously in the Asthma Therapeutics Market.Technology Analysis
The technology analysis involves evaluating the current and emerging technologies relevant to a specific industry or market. This analysis includes breakthrough trends across the value chain that directly define the future course of long-term profitability and overall advancement in the Asthma Therapeutics Market.Patent Analysis
The patent analysis involves evaluating patent filing trends, assessing patent ownership, analyzing the legal status and compliance, and collecting competitive intelligence from patents within the Asthma Therapeutics Market and its parent industry. Analyzing the ownership of patents, assessing their legal status, and interpreting the patents to gather insights into competitors' technology strategies assist businesses in strategizing and optimizing product positioning and investment decisions.Trade Analysis
The trade analysis of the Asthma Therapeutics Market explores the complex interplay of import and export activities, emphasizing the critical role played by key trading nations. This analysis identifies geographical discrepancies in trade flows, offering a deep insight into regional disparities to identify geographic areas suitable for market expansion. A detailed analysis of the regulatory landscape focuses on tariffs, taxes, and customs procedures that significantly determine international trade flows. This analysis is crucial for understanding the overarching legal framework that businesses must navigate.Regulatory Framework Analysis
The regulatory framework analysis for the Asthma Therapeutics Market is essential for ensuring legal compliance, managing risks, shaping business strategies, fostering innovation, protecting consumers, accessing markets, maintaining reputation, and managing stakeholder relations. Regulatory frameworks shape business strategies and expansion initiatives, guiding informed decision-making processes. Furthermore, this analysis uncovers avenues for innovation within existing regulations or by advocating for regulatory changes to foster innovation.FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Asthma Therapeutics Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Asthma Therapeutics Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.Recent Developments
GSK Boosts Respiratory Portfolio with $1.4 Billion Aiolos Bio Acquisition
GlaxoSmithKline PLC has announced the acquisition of Aiolos Bio Inc. with an investment of USD 1.4 billion. This acquisition aims to enhance GSK's foothold in the asthma treatment market as this deal gives GSK access to AIO-001, a cutting-edge asthma therapy by Aiolos Bio.Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma
Teva Pharmaceutical Industries Ltd. and Biolojic Design Ltd. announced an exclusive license agreement to develop a potential novel antibody-based therapy for treating Atopic Dermatitis and Asthma. BD9 is novel for its dual-action mechanism that inhibits both TSLP and IL-13, offering a more comprehensive treatment option over current single-target therapies. This collaboration is a strategic move complementing Teva's 'Pivot to Growth' strategy, which was unveiled in May 2023 and focuses on stoking innovation through partnerships and enhancing Teva's early-stage pipeline.Lupin Launches Luforbec® 100/6 for Adult Asthma and COPD Treatment
Hormosan Pharma GmbH, a fully owned subsidiary of Lupin Limited, announced the launch of Luforbec 100/6, a fixed blend in a pressurized metered dose inhaler (pMDI) for the remedy of adult chronic obstructive pulmonary disease (COPD) and asthma in Germany.Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Asthma Therapeutics Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.Key Company Profiles
The report delves into recent significant developments in the Asthma Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Amgen Inc., AstraZeneca PLC, Biogen Inc., Boehringer Ingelheim GmbH, Boston Scientific Corporation, Chiesi Farmaceutici S.p.A., Cipla Limited, F. Hoffmann-La Roche Ltd, Genentech, Inc., GlaxoSmithKline PLC, Kare Medical and Analytical Devices Ltd. Co., Koninklijke Philips N.V., Lupin Limited, Medtronic PLC, Merck & Co, Inc., Merxin Ltd., Novartis AG, Parekhplast India Limited, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A., Shenzhen Aeon Technology Co., Ltd., Softhale NV by invoX Pharma Limited, Sun Pharmaceutical Industries Limited, Sunovion Pharmaceuticals, Inc., Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Ltd., Trudell Medical Limited, Viatris Inc., and Wellinks, Inc..Market Segmentation & Coverage
This research report categorizes the Asthma Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:- Product
- Inhalers
- Dry Powder Inhalers
- Metered-Dose Inhalers
- Soft Mist Inhalers
- Nebulizers
- Inhalers
- Drug Class
- Anti-Inflammatory
- Bronchodilators
- Combination Therapy
- Route of administration
- Inhaled
- Oral
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
This research report offers invaluable insights into various crucial aspects of the Asthma Therapeutics Market:
- Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
- Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
- Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
- Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
- Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.
Additionally, the report addresses key questions to assist stakeholders in making informed decisions:
- What is the current market size and projected growth?
- Which products, segments, applications, and regions offer promising investment opportunities?
- What are the prevailing technology trends and regulatory frameworks?
- What is the market share and positioning of the leading vendors?
- What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?
Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report
Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.
With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.
This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.
Table of Contents
1. Preface
2. Research Methodology
5. Market Insights
6. Asthma Therapeutics Market, by Product
7. Asthma Therapeutics Market, by Drug Class
8. Asthma Therapeutics Market, by Route of administration
9. Americas Asthma Therapeutics Market
10. Asia-Pacific Asthma Therapeutics Market
11. Europe, Middle East & Africa Asthma Therapeutics Market
12. Competitive Landscape
13. Competitive Portfolio
List of Figures
List of Tables
Companies Mentioned
- Abbott Laboratories
- Amgen Inc.
- AstraZeneca PLC
- Biogen Inc.
- Boehringer Ingelheim GmbH
- Boston Scientific Corporation
- Chiesi Farmaceutici S.p.A.
- Cipla Limited
- F. Hoffmann-La Roche Ltd
- Genentech, Inc.
- GlaxoSmithKline PLC
- Kare Medical and Analytical Devices Ltd. Co.
- Koninklijke Philips N.V.
- Lupin Limited
- Medtronic PLC
- Merck & Co, Inc.
- Merxin Ltd.
- Novartis AG
- Parekhplast India Limited
- Pfizer Inc.
- Regeneron Pharmaceuticals, Inc.
- Sanofi S.A.
- Shenzhen Aeon Technology Co., Ltd.
- Softhale NV by invoX Pharma Limited
- Sun Pharmaceutical Industries Limited
- Sunovion Pharmaceuticals, Inc.
- Takeda Pharmaceutical Company
- Teva Pharmaceutical Industries Ltd.
- Trudell Medical Limited
- Viatris Inc.
- Wellinks, Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 186 |
| Published | May 2024 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 27.26 Billion |
| Forecasted Market Value ( USD | $ 50.1 Billion |
| Compound Annual Growth Rate | 10.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 31 |
